Stocktoria

Scilex Holding Co SCLX

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-11
Chart by TradingView
3/9
Piotroski F — financial health
-22.99
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$30.3M$56.6M$46.7M$38.0M$31.3M
Gross profit$125.8M$167.4M
Operating income-$346.0M-$83.4M-$105.4M-$50.6M-$35.8M
Net income-$374.1M-$72.8M-$114.3M-$23.4M-$88.4M
Operating cash flow$3.8M$19.3M-$20.7M-$21.3M-$28.7M
Free cash flow$3.7M$19.3M-$20.7M-$21.3M-$28.7M
Total assets$365.0M$93.0M$101.3M$86.5M$77.9M
Total liabilities$576.7M$285.6M$274.2M$50.3M$301.8M
Shareholders' equity-$211.8M-$192.6M-$172.9M$36.2M-$223.9M
Ratios
Gross margin415.8%295.8%
Operating margin-1143.7%-147.4%-225.6%-133.1%-114.4%
Net margin-1236.4%-128.7%-244.6%-61.4%-282.4%
FCF margin12.2%34.2%-44.4%-55.9%-91.5%
Return on assets-102.5%-78.3%-112.9%-27.0%-113.5%
Return on equity176.6%37.8%66.1%-64.5%39.5%
Debt / equity0.00×-0.32×
Current ratio0.080.160.190.660.14
Revenue growth-46.5%21.1%22.9%21.4%32.9%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC36,864$245,514

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -22.99 (distress)

  • Working capital / assets -1.22
  • Retained earnings / assets -2.526
  • EBIT / assets -0.948
  • Equity / liabilities -0.367

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001820190 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.